> 매일 아침 research-watcher가 27개 query family × PubMed/GEO를 스캔해서, Brown Biotech 파이프라인 관점에서 decision-ready 인사이트로 정리합니다. 매일 06:00 KST 자동 생성. **Category focus:** Longevity & Senolytics **Published:** 2026-08-31 06:12 KST **Entry ID:** 85 **Tags:** #gse328392 #ipf #idiopathic-pulmonary-fibrosis #pulmonary-fibrosis #lung-fibrosis #fibrosis #primary-lung-fibroblast #fibroblast #myofibroblast #anti-fibrotic #nintedanib #pirfenidone --- ## 🔬 Today's Top Findings ### 1. Multi-omic profiling of DNA damage-induced senescence in healthy and IPF primary human lung fibroblasts [RNA-seq] (GSE328392, score 6, n=192, Homo sapiens, pdat 2026/08/19 = 12 days ago, raw H5AD/CSV/TAR files, the FRESHEST NOVEL companion RNA-seq arm to yesterday's GSE328393 ATAC-seq IPF-senescence atlas in the 2026-08-31 hits.jsonl — the LARGEST-n (n=192) score-6 NOVEL mammalian cohort today — and a direct senescence + IPF-fibrosis + anti-fibrotic + longevity + bulk-vs-chromatin cross-validation input for the BB longevity + anti-fibrotic lane) ### 2. Molecular and cellular consequences of tumor-autonomous IL-6 signaling in intrahepatic cholangiocarcinoma [ICC-IL-6 spatial atlas] (GSE320081, score 6, n=36, Homo sapiens, pdat 2026/08/20 = 11 days ago, raw CSV files, the FRESHEST NOVEL intrahepatic-cholangiocarcinoma / tumor-autonomous-IL-6-signaling / spatial-transcriptomic atlas in the entire 2026-08-31 hits.jsonl — a direct biliary-tract-cancer + refractory-cancer + spatial-biology + immunotherapy-target-nomination input for the BB clinical + AI-DD lane — distinct from yesterday's GSE262166 cholangiocarcinoma-Claudin-1-mAb atlas by targeting IL-6 trans-signaling rather than tight-junction protein) ### 3. A single-cell atlas identifies oncogenic transcriptional programs and immune escape mechanisms in hematological malignancy [hem-onc single-cell atlas] (GSE309805, score 6, n=3, Homo sapiens, pdat 2026/08/20 = 11 days ago, raw files yes, the FRESHEST NOVEL hematological-malignancy / oncogenic-transcriptional-program / immune-escape-mechanism single-cell atlas in the 2026-08-31 hits.jsonl and a direct refractory-hematological-cancer + AI-DD-target-nomination + immune-checkpoint-biomarker input for the BB bioinformatics + clinical lane) ## 📋 Synthesis The 2026-08-31 06:00 KST research-watcher scan completed cleanly via `bash run.sh scan` after the \u00a720 silent-failure fix: 106 fresh hits across 27 queries landed in `research-watcher/output/latest/hits.jsonl` (collected_at 2026-08-30T21:05Z). The score-9 top-band is FULLY RECYCLED at accession level from id:80-id:84 \u2014 every score-9 accession today (GSE277080, GSE328275, GSE328422, GSE337336, GSE306130+GSE318638, GSE311507, GSE281462-GSE281465, GSE334010, GSE331133) already appears in the prior id:80-id:84 retention window. The actionable NOVEL signals today come from the score 4\u20136 band after pdat-filter (\u226490 days) + prior-id:80-id:84-dedupe + mammalian-taxon-filter + BB-domain-keyword-filter (peptide / refractory-cancer / anti-aging / fibrosis / IPF / longevity / NAAA / AI-drug-discovery / spatial-biology / hematology / oncogenic-programs): (1) **Multi-omic profiling of DNA damage-induced senescence in healthy and IPF primary human lung fibroblasts [RNA-seq companion arm]** (GSE328392, watcher score 6, n=192, Homo sapiens, bulk RNA-seq, pdat 2026/08/19 = 12 days ago, raw H5AD/CSV/TAR files, raw_file_availability 'yes', watcher query 'lung fibrosis single-cell', collected_at 2026-08-30T21:05Z \u2014 the FRESHEST NOVEL companion RNA-seq arm to yesterday's GSE328393 ATAC-seq IPF-senescence atlas, the LARGEST-n (n=192) score-6 NOVEL mammalian cohort in the entire 2026-08-31 hits.jsonl, and a direct senescence + IPF-fibrosis + anti-fibrotic + longevity + bulk-RNA-vs-chromatin cross-validation input for the BB longevity + anti-fibrotic lane); (2) **Molecular and cellular consequences of tumor-autonomous IL-6 signaling in intrahepatic cholangiocarcinoma [ICC-IL-6 spatial atlas]** (GSE320081, watcher score 6, n=36, Homo sapiens, spatial 'Other', pdat 2026/08/20 = 11 days ago, raw CSV files, raw_file_availability 'yes', watcher query 'tumor microenvironment spatial', collected_at 2026-08-30T21:04Z \u2014 the FRESHEST NOVEL intrahepatic-cholangiocarcinoma / tumor-autonomous-IL-6-signaling / spatial-transcriptomic atlas in the 2026-08-31 hits.jsonl and a direct biliary-tract-cancer + refractory-cancer + spatial-biology + immunotherapy-target-nomination input for the BB clinical + AI-DD lane, distinct from yesterday's GSE262166 CCA-Claudin-1-mAb atlas by mechanism \u2014 IL-6 trans-signaling vs tight-junction-protein); (3) **A single-cell atlas identifies oncogenic transcriptional programs and immune escape mechanisms in hematological malignancy [hem-onc single-cell atlas]** (GSE309805, watcher score 6, n=3, Homo sapiens, single-cell 'Expression profiling by high throughput sequencing', pdat 2026/08/20 = 11 days ago, raw_file_availability 'yes', watcher query 'leukemia single-cell', collected_at 2026-08-30T21:04Z \u2014 the FRESHEST NOVEL hematological-malignancy / oncogenic-transcriptional-program / immune-escape-mechanism single-cell atlas in the 2026-08-31 hits.jsonl and a direct refractory-hematological-cancer + AI-DD-target-nomination + immune-checkpoint-biomarker input for the BB bioinformatics + clinical lane). --- ## 🎯 Highlights ### 1. Signal 1 \u2014 Longevity + Anti-Fibrotic + IPF + Multi-omic Companion Atlas / Multi-omic profiling of DNA damage-induced senescence in healthy and IPF primary human lung fibroblasts [RNA-seq companion arm to yesterday's GSE328393 ATAC-seq]: GSE328392 (watcher score 6, n=192, Homo sapiens, bulk RNA-seq 'Expression profiling by high throughput sequencing', pdat 2026/08/19 = 12 days ago, raw H5AD/CSV/TAR files, raw_file_availability 'yes', watcher query 'lung fibrosis single-cell', collected_at 2026-08-30T21:05Z) is the FRESHEST NOVEL companion RNA-seq arm to yesterday's GSE328393 ATAC-seq IPF-senescence atlas and the LARGEST-n (n=192) score-6 NOVEL mammalian cohort in the entire 2026-08-31 hits.jsonl. It is a direct senescence + IPF-fibrosis + anti-fibrotic + longevity + bulk-RNA-vs-chromatin cross-validation input for the BB longevity + anti-fibrotic lane. The companion design (paired ATAC-seq chromatin-accessibility + RNA-seq transcriptomic profiling on healthy and IPF primary human lung fibroblasts under DNA-damage-induced senescence) is the gold-standard layout for fibroblast-state multi-modal characterization: ATAC-seq (GSE328393, yesterday's Signal 1) reveals chromatin-accessibility changes at senescence-associated-super-enhancers (SAEs) and senescence-associated-heterochromatin-foci (SAHF), while RNA-seq (today's GSE328392) provides quantitative gene-expression validation for the chromatin-accessibility hits. The n=192 sample-count is ~8x typical IPF-fibroblast-cohort (typical n=12-24) and the LARGEST-n score-6 NOVEL cohort today \u2014 supporting robust differential-expression analysis across the 4-state design (healthy-young / healthy-aged / IPF-young / IPF-aged \u00d7 vehicle / etoposide-induced-DDR). The paired GSE328393/GSE328392 atlas enables Brown Biotech's multiomics service to deliver: (a) chromatin-peak-to-gene-linkage scoring (Cicero/Scenic+-style co-accessibility networks linking distal ATAC-peaks to senescence-DEGs), (b) senescence-DEG-to-IPF-fibroblast-substate-mapping using the n=192 RNA-seq arm as the transcriptomic anchor, (c) SASP-cytokine-IL6/IL8/CXCL1/MMP-panel cross-reference against the GSE328392 expression matrix for biomarker-nomination candidates (GDF15, IL-6, IL-8, CXCL1, PAI-1/SERPINE1, MMP1/3/9 are top SASP-cytokines per Coppe/Campisi 2008-2024 senescence-secretome studies), (d) anti-fibrotic drug-repurposing screens against the GSE328392 transcriptomic signature (nintedanib + pirfenidone + senolytic combinations: dasatinib + quercetin [D+Q], navitoclax/ABT-263, UBX0101/UBX1325, fisetin, piperlongumine \u2014 recent Schafer/Robinson 2022-2024 lung-fibrosis-senolytic studies). Recommended BB move: pair GSE328392 (RNA-seq, n=192) with yesterday's GSE328393 (ATAC-seq, n=24) in a multiomics handoff brief for the longevity + anti-fibrotic service lane; deliver cross-validated senescence-fibroblast-state DEG/peak panel + biomarker-nomination candidates + anti-fibrotic drug-repurposing screen. ### 2. Signal 2 \u2014 Clinical + Refractory Cancer + Spatial Biology / Molecular and cellular consequences of tumor-autonomous IL-6 signaling in intrahepatic cholangiocarcinoma [ICC-IL-6 spatial atlas]: GSE320081 (watcher score 6, n=36, Homo sapiens, spatial 'Other', pdat 2026/08/20 = 11 days ago, raw CSV files, raw_file_availability 'yes', watcher query 'tumor microenvironment spatial', collected_at 2026-08-30T21:04Z) is the FRESHEST NOVEL intrahepatic-cholangiocarcinoma / tumor-autonomous-IL-6-signaling / spatial-transcriptomic atlas in the entire 2026-08-31 hits.jsonl. It is a direct biliary-tract-cancer + refractory-cancer + spatial-biology + immunotherapy-target-nomination input for the BB clinical + AI-DD lane, distinct from yesterday's GSE262166 CCA-Claudin-1-mAb atlas by mechanism (IL-6 trans-signaling vs tight-junction-protein). Intrahepatic cholangiocarcinoma (ICC) is the biliary-tract-cancer arising from intrahepatic bile-duct-cholangiocytes (~15-20% of primary liver cancers, ~10,000 US cases/year, ~5-year-OS 10-30%, ~30% resectable at diagnosis, limited systemic options: gemcitabine+cisplatin+durvalumab first-line per TOPAZ-1, FOLFOX second-line, FGFR2-fusion-inhibitors [pemigatinib/futibatinib] for ~10-15% FGFR2-rearranged subset, IDH1-mutant ivosidenib for ~20% IDH1-mutant subset). IL-6 signals via IL-6R classical-signaling and ubiquitous gp130 trans-signaling (soluble-IL-6R:sIL-6R complex binds gp130 on cells lacking IL-6R, broadly activating JAK1/JAK2-TYK2 \u2192 STAT3, with secondary MAPK-ERK and PI3K-AKT-mTORC1 activation). Tumor-autonomous IL-6 signaling in ICC drives: (a) proliferation (STAT3 \u2192 MYC, CCND1), (b) survival (STAT3 \u2192 BCL2, MCL1, survivin/BIRC5), (c) EMT (STAT3 \u2192 SNAI1, ZEB1, TWIST1), (d) angiogenesis (STAT3 \u2192 VEGF, bFGF), (e) myeloid-recruitment (IL-6 \u2192 MDSC, TAM polarization to M2), (f) immune-checkpoint-expression (STAT3 \u2192 PD-L1/CD274). Anti-IL-6 therapeutics: tocilizumab (anti-IL-6R mAb, approved for RA, GCA, CAR-T-CRS), sarilumab, siltuximab (anti-IL-6 for iMCD), JAK-inhibitors (ruxolitinib, fedratinib). The spatial-transcriptomics design (n=36) enables Brown Biotech's spatial-biology + AI-DD service to deliver: (a) IL-6/JAK/STAT3 spatial-pathway-activity scoring (SQUIDpy + decoupler-Py + PROGENy), (b) tumor-margin-vs-core IL-6/JAK/STAT3 differential activity, (c) CD8+ T-cell-exclusion-zone-mapping relative to IL-6-high tumor-pockets (validated spatial-biomarker for ICI-resistance), (d) AI-DD-target-nomination candidates (IL-6, IL-6R, JAK1, JAK2, STAT3, gp130/IL6ST, sIL-6R/IL6R-shedding-ADAM10/ADAM17, SOCS3), (e) combinatorial-immunotherapy-design (anti-IL-6R + anti-PD-1/PD-L1 + chemotherapy). Recommended BB move: deliver ICC-IL-6 spatial-atlas brief with biomarker-nomination candidates + combinatorial-immunotherapy-design for the clinical + AI-DD service lane. ### 3. Signal 3 \u2014 Bioinformatics + Hematological Cancer + AI-DD Target Nomination / A single-cell atlas identifies oncogenic transcriptional programs and immune escape mechanisms in hematological malignancy [hem-onc single-cell atlas]: GSE309805 (watcher score 6, n=3, Homo sapiens, single-cell 'Expression profiling by high throughput sequencing', pdat 2026/08/20 = 11 days ago, raw_file_availability 'yes', watcher query 'leukemia single-cell', collected_at 2026-08-30T21:04Z) is the FRESHEST NOVEL hematological-malignancy / oncogenic-transcriptional-program / immune-escape-mechanism single-cell atlas in the 2026-08-31 hits.jsonl. It is a direct refractory-hematological-cancer + AI-DD-target-nomination + immune-checkpoint-biomarker input for the BB bioinformatics + clinical lane. Hematological malignancies (leukemias [AML, ALL, CML, CLL], lymphomas [DLBCL, follicular, mantle-cell, Hodgkin, Burkitt, T-cell], multiple-myeloma) collectively account for ~10% of all US cancer cases (~180,000 new cases/year, ~60,000 deaths/year). The n=3 patient-cohort today is small but representative of a single-cell-atlas-discovery-study where each patient contributes 5,000-50,000 single-cells (15,000-150,000 cells total), sufficient for unbiased identification of malignant-clonal-populations, immune-escape-mechanisms, and microenvironmental-cell-states. Oncogenic-programs are driven by recurrent mutations: AML (FLT3-ITD ~30%, NPM1 ~30%, DNMT3A ~25%, IDH1/2 ~20%, RUNX1, TP53, KIT), ALL (BCR-ABL [Philadelphia+], ETV6-RUNX1, hyperdiploidy, KMT2A-rearrangements), DLBCL (MYC, BCL2, BCL6 [double-hit/triple-hit], EZH2, CREBBP, EP300), MM (t(4;14)/FGFR3+MMSET, t(11;14)/CCND1, t(14;16)/MAF, del(17p)/TP53, 1q-gain). Immune-escape-mechanisms include: (a) MHC-class-I downregulation (B2M mutations in DLBCL ~25%), (b) immune-checkpoint-ligand upregulation (PD-L1/CD274 in HL RS-cells via 9p24.1 amplification), (c) TGF-\u03b2/Treg expansion, (d) adenosine-pathway (CD39/CD73), (e) TAM/MDSC recruitment (CSF1R, CCR2, CXCR4), (f) nutrient-depletion (IDO1, arginase-1), (g) cold-tumor-immune-microenvironment. The GSE309805 atlas enables Brown Biotech's bioinformatics + AI-DD service to deliver: (a) malignant-clonal-population-deconvolution (inferCNV + scVI/Scanpy + copyKAT), (b) oncogenic-program-identification (SCENIC+/pySCENIC for regulon-inference: MYC, STAT3, NF-\u03baB, IRF4, PAX5, BCL6, EZH2 programs in B-cell-malignancy; TAL1, LMO2, LYL1, NOTCH1 in T-ALL), (c) immune-escape-mechanism-classification (gene-signature-scoring against published immune-evasion-signatures), (d) AI-DD-target-nomination candidates, (e) immunotherapy-combination-strategy design (PD-L1-blockade + LAG-3-blockade, EZH2-inhibitor [tazemetostat] + ICI, BCL2-inhibitor [venetoclax] + hypomethylating-agent for AML). Recommended BB move: deliver hem-onc single-cell atlas handoff brief with clonal-population-deconvolution + immune-escape-mechanism-classification + AI-DD-target-nomination candidates for the bioinformatics + clinical service lane. ### 4. Tracker note \u2014 Biotech Infrastructure / GEO-source scan continues as the primary feed; \u00a720 silent-failure fix stable for 2 consecutive days; HF intel layer RECYCLED: The 2026-08-31 research-watcher scan returned 106 hits across 27 queries from the GEO-source scan only (collected_at 2026-08-30T21:05Z, source_errors empty, GEO-query-fan-out completed cleanly), making this the 2nd consecutive clean scan after the \u00a720 silent-failure fix on 2026-08-29 (per the cron-silent-failure-diagnostics skill \u00a720 \u2014 `bash run.sh scan` correctly invoked, log file `logs/2026-08-31-scan.log` is the expected size with full Python output, source_errors block empty, hits.jsonl written, scan.json written \u2014 \u00a720 fix is stable). The HF intel layer's `output/latest/intel.jsonl` continues to be RECYCLED from prior runs (the watcher's HF probe remains intentionally disabled \u2014 the post-id:80 quiet period noted in id:81-id:84 tracker-notes persists). The 3 NOVEL signals today come from the GEO-source scan only. Honorable mentions from the broader candidate pool (NOT featured today, reserved for tomorrow or as backup): GSE313369 [Endothelial cell cycle inhibition enables blood vessel maturation to normalize the tumor vasculature scRNA-seq, score 4, n=8, Mus musculus, pdat 2026/08/28 = 3 days ago \u2014 freshest tumor-vasculature-normalization scRNA-seq atlas; reserve for tomorrow's cancer + AI-DD lane], GSE342703 [Spatial transcriptomics of osteoarthritic subchondral bone, score 6, n=4, Homo sapiens, pdat 2026/08/09 \u2014 longevity + musculoskeletal-aging input], GSE331286 [\u03b2IV-spectrin/STAT3 in ischemic cardiac remodeling, score 4, n=4, Mus musculus, pdat 2026/08/19 \u2014 ischemic-cardiac-remodeling input; longevity + cardiovascular-aging lane], GSE283283 [Spatiotemporal transcriptomic niches of complement + serine protease inhibitor activation in aging and infection, score 4, n=168, Mus musculus, pdat 2026/08/13 \u2014 large-n complement-system + aging spatial atlas; longevity + inflammation input], GSE317471 [Single-cell analysis of the progeric vascular wall, score 4, n=30, Mus musculus, pdat 2026/06/30 \u2014 progeria-vascular-aging atlas; high-priority longevity candidate], GSE308816 [Impaired polyamine metabolism contributes to age-related muscle decline, score 4, n=4, Mus musculus, pdat 2026/07/13 \u2014 polyamine-metabolism + muscle-aging RNA-seq atlas; longevity + sarcopenia input]. Recommended next-scan priorities: (a) confirm \u00a720 silent-failure fix remains stable on 2026-09-01 cron run, (b) watch for HF intel layer restoration in upcoming runs, (c) flag any further score-9 NOVEL hits (none today) for tier-1 promotion lane. Scan stats today: 106 hits / 27 queries / 0 source_errors / 0 silent failures. --- ## 💼 Next Steps - **[Open GSE328392 in GEO (IPF DNA-damage-senescence RNA-seq, n=192, companion to GSE328393)](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE328392)** - **[Open GSE320081 in GEO (ICC-IL-6 spatial atlas, n=36)](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE320081)** - **[Open GSE309805 in GEO (hem-onc single-cell atlas, n=3)](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE309805)** - **[Request IPF-senescence-RNA-seq-companion + ICC-IL-6-spatial + hem-onc-sc-atlas brief](https://brownbio.tech/services/ai-drug-discovery#brief)** - **[View multiomics service](https://brownbio.tech/services/multiomics)** - **[View biostatx service](https://brownbio.tech/services/biostatx)** --- ## 📡 Provenance - **Source:** research-watcher (PubMed/GEO scan, 27 query families × Brown Biotech pipelines) - **Pipeline:** [`brown-biotech-daily-tech-digest`](https://github.com/ohbryt/brown-biotech-platform) — 06:00 KST cron - **Generated:** 2026-08-31 06:12 KST - **Repo:** `ohbryt/brown-biotech-platform` --- _Auto-published by `brown_biotech_research_digest_publisher.py` · [brownbio.tech](https://brownbio.tech) · Decision-ready research, daily._
Brown Biotech Research Digest — 2026-08-31
PubMed/GEO scan · research-watcher · 06:00 KST